title: Effect of tamoxifen citrate on reproductive parameters of male dogs.
abstract: Tamoxifen is a synthetic, nonsteroidal Type I antiestrogenic compound that competitively blocks estrogen receptors with a mixed antagonist-agonist effect. The manifestation of these different actions depends on each species, organ, tissue and cell type considered. Very little is known about the effect of antiestrogens in dogs. The objectives of this study were to determine the effects of tamoxifen citrate on some testis, prostate, hormone, and semen parameters in seven Beagle dogs with uncomplicated spontaneous benign prostatic hyperplasia. Two dogs were normospermic, four were oligozoospermic, and one was azoospermic. The dogs were allocated to a control pre-treatment period, followed by a treatment period, and five post-treatment periods (the duration of each period was 4 weeks). During the treatment period, 2.5mg tamoxifen citrate was given p.o. daily for 28 days to all the dogs. Maximum scrotal width, testicular consistency, libido semen parameters, prostatic volume, serum testosterone concentrations, and side effects were assessed. Tamoxifen negatively affected testis size and libido (P<0.01), and decreased prostatic volume (P<0.01) and testosterone concentrations during treatment. Semen quality deteriorated to nadir values (P<0.01) approximately one spermatic cycle after treatment and returned to pre-treatment values on the second cycle after treatment in all the dogs, except one young oligoazoospermic dog, in which the sperm count was higher ( P<0.01 ) at that time. No side effects were observed and fertility was conserved at the end of the study. Tamoxifen acted more like an agonist than antagonist on the gonadal axis and, therefore, upon both the prostate and testis. Therefore, tamoxifen may have therapeutic applications in dogs.
authors.affiliation: Small Animal Clinic & Imaging Diagnose Service, Faculty of Veterinary Medicine, National University of La Plata, La Plata, Argentina. cgobello@fcv.unlp.edu.ar
authors.forename: Y
authors.initials: Y
authors.lastname: Corrada
authors.forename: D
authors.initials: D
authors.lastname: Arias
authors.forename: R
authors.initials: R
authors.lastname: Rodríguez
authors.forename: E
authors.initials: E
authors.lastname: Spaini
authors.forename: F
authors.initials: F
authors.lastname: Fava
authors.forename: C
authors.initials: C
authors.lastname: Gobello
mesh_terms: D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy; D004285:Dogs / Q000502:physiology*; D004965:Estrogen Antagonists / Q000494:pharmacology*; D008297:Male; D011467:Prostate / Q000033:anatomy & histology / Q000000981:diagnostic imaging / Q000187:drug effects; D011470:Prostatic Hyperplasia / Q000188:drug therapy / Q000662:veterinary; D012098:Reproduction / Q000187:drug effects*; D012611:Scrotum / Q000033:anatomy & histology / Q000187:drug effects; D012661:Semen / Q000187:drug effects; D012726:Sexual Behavior, Animal / Q000187:drug effects; D013076:Sperm Count; D013081:Sperm Motility / Q000187:drug effects; D013629:Tamoxifen / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D013737:Testis / Q000187:drug effects; D013739:Testosterone / Q000097:blood; D014463:Ultrasonography
chemical_list: D004965:Estrogen Antagonists; D013629:Tamoxifen; D013739:Testosterone